Senseonics Holdings

Eversense is a fluorescence-based sensor implanted subcutaneously by a physician in a five-minute procedure, then removed and replaced every 180 days. Abbott and Dexcom sensors sit partially in the skin using a needle-based architecture and are self-applied every 10 to 15 days. The implant approach trades insertion convenience for duration — the patient interacts with the sensor hardware twice per year rather than twice per month, and the transmitter worn over the implant is a removable, rechargeable component rather than a disposable unit attached to each new sensor.

Senseonics is a publicly traded operating company on the NYSE American, not an investment firm or family office. Capital allocation decisions — including equity offerings, manufacturing expansion, and R&D spend — are made by CEO Tim Goodnow and the board of directors, and disclosed through SEC filings. There is no investment committee in the allocator sense; the firm's cash is deployed against the commercialization of its single Eversense product line and debt service on its convertible notes.

Ascensia Diabetes Care holds exclusive global distribution rights for Eversense outside the United States under the 2020 agreement, covering key European markets including Germany, Italy, and Spain as well as selected Middle Eastern geographies. Senseonics retains its own direct sales force for the US market and receives a royalty on Ascensia's ex-US sales tied to sensor insertion volumes.

As of year-end 2024, Senseonics reported roughly $43 million in cash and equivalents, augmented by a $21 million direct offering closed in January 2025 (per the firm, January 2025). The company has historically funded operations through a combination of equity offerings, convertible debt — including a 2023 exchange transaction that reduced outstanding 2025 notes — and product revenue. The firm does not publish an AUM and is not a pooled investment vehicle.

The Eversense E3 system is FDA-cleared for adults with all types of diabetes. In practice, physician adoption has concentrated among insulin-requiring patients — both Type 1 and intensive insulin-using Type 2 — where continuous glucose data drives immediate therapeutic decisions. The firm has publicly stated it intends to broaden reach into basal-insulin and non-insulin Type 2 populations as insertion volumes grow, but near-term prescriber penetration is weighted toward insulin-dependent cohorts.

CEO Tim Goodnow was vice president of research and development at TheraSense, a glucose-sensing company acquired by Abbott in 2004 for $1.2 billion. Goodnow founded Senseonics in 1996 before TheraSense was sold. The technical lineage matters: TheraSense commercialized a wired-enzyme sensor technology that became foundational to Abbott's FreeStyle line, while Senseonics chose fluorescence chemistry — a parallel technical bet by the same executive generation on the same disease state, with an opposing architecture.